indications for glp-1 Oral semaglutide (Rybelsus) is the 4th receptor agonist formulation to receive FDA approval to reduce the risk of major cardiovascular events in patients with type 2 diabetes. Our GLP-1 Agonist chart Long-term Success of GLP-1s Hinges
Description
Jesper Lau, Thomas Kruse and Paw Bloch, credit: Jesper Lau
This review aims to summarize the findings from CVOTs of GLP-1RAs, explore the latest data on dual and tri-agonist therapies, and delve into potential mechanisms contributing to their cardioprotective effects
In a trial consisting of diabetic and hypertensive patients with a mean HbA1c of 8.59, empagliflozin, compared to placebo, showed a lower number of cerebrovascular events [37]
Understanding the balance between the beneficial effects and potential metabolic side effects of -blockers is crucial for optimizing their clinical use
This dose-independent pricing model eliminates the financial burden that typically discourages patients from achieving optimal therapeutic dosing
Semaglutide for adults living with obesity
